Role of exosomal non‑coding RNAs in cancer‑associated fibroblast‑mediated therapy resistance (Review).

IF 4.9 3区医学 Q1 ONCOLOGY

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-19 DOI:10.3892/ijo.2025.5774

Junxin Li, Yu Huang, Lin Fu, Ming Shi, Gongli Hu, Fei Du, Zhongshu Wang, Yi Xiao, Yan Zhang, Yanyu Li

{"title":"Role of exosomal non‑coding RNAs in cancer‑associated fibroblast‑mediated therapy resistance (Review).","authors":"Junxin Li, Yu Huang, Lin Fu, Ming Shi, Gongli Hu, Fei Du, Zhongshu Wang, Yi Xiao, Yan Zhang, Yanyu Li","doi":"10.3892/ijo.2025.5774","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer‑associated fibroblasts (CAFs) represent an important component of the stromal cell population within the tumor microenvironment (TME) and are intricately linked to tumor growth, metastasis and drug resistance. In the TME, non‑coding RNAs present in exosomes act as essential mediators of intercellular communication. Exosomal RNAs derived from cancer cells activate CAFs, which in turn regulate cancer cell proliferation, invasion and drug resistance. Conversely, exosomal RNAs derived from CAFs contribute to therapeutic resistance in cancer by modulating survival signaling pathways, epithelial‑mesenchymal transition, programmed cell death, drug transporter expression levels and immune evasion. The present review examines the role and mechanisms of exosomal RNAs in CAF‑mediated cancer therapeutic resistance and offers recommendations for future research based on the underlying mechanisms of CAF‑induced drug resistance.</p>","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 2","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274182/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijo.2025.5774","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer‑associated fibroblasts (CAFs) represent an important component of the stromal cell population within the tumor microenvironment (TME) and are intricately linked to tumor growth, metastasis and drug resistance. In the TME, non‑coding RNAs present in exosomes act as essential mediators of intercellular communication. Exosomal RNAs derived from cancer cells activate CAFs, which in turn regulate cancer cell proliferation, invasion and drug resistance. Conversely, exosomal RNAs derived from CAFs contribute to therapeutic resistance in cancer by modulating survival signaling pathways, epithelial‑mesenchymal transition, programmed cell death, drug transporter expression levels and immune evasion. The present review examines the role and mechanisms of exosomal RNAs in CAF‑mediated cancer therapeutic resistance and offers recommendations for future research based on the underlying mechanisms of CAF‑induced drug resistance.

Abstract Image

查看原文本刊更多论文

外泌体非编码rna在癌症相关成纤维细胞介导的治疗耐药性中的作用（综述）。

肿瘤相关成纤维细胞（Cancer - associated fibroblasts, CAFs）是肿瘤微环境（tumor microenvironment， TME）中基质细胞群的重要组成部分，与肿瘤生长、转移和耐药性有着复杂的联系。在TME中，存在于外泌体中的非编码rna作为细胞间通讯的基本介质。来自癌细胞的外泌体rna激活cas，进而调节癌细胞的增殖、侵袭和耐药性。相反，来自CAFs的外泌体rna通过调节生存信号通路、上皮-间充质转化、程序性细胞死亡、药物转运蛋白表达水平和免疫逃避，有助于癌症的治疗耐药。本文综述了外泌体rna在CAF介导的癌症耐药中的作用和机制，并根据CAF诱导的耐药机制为未来的研究提出了建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of oncology 医学-肿瘤学

CiteScore

9.60

自引率

0.00%

发文量

157

审稿时长

2.1 months

期刊介绍： The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality. The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research. All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.